PTLD risk associated with HCV status at the time of transplantation among 210 763 solid organ transplant recipients by PTLD subtype and type of organ transplanted
| . | Patients with PTLD, no. . | HCV+, HR (95% CI)* . | HCV status unknown, HR (95% CI)* . |
|---|---|---|---|
| Total | 1630 | 0.84 (0.68-1.05) | 0.84 (0.73-0.98) |
| By PTLD site | |||
| Liver | 208 | 1.06 (0.62-1.82) | 0.93 (0.62-1.40) |
| Nonliver | 1422 | 0.81 (0.64-1.03) | 0.83 (0.71-0.97) |
| Allograft | 266 | 1.11 (0.68-1.79) | 1.09 (0.78-1.54) |
| Nonallograft | 1364 | 0.80 (0.63-1.01) | 0.80 (0.68-0.94) |
| By PTLD pathology† | |||
| Polymorphic | 584 | 0.99 (0.69-1.41) | 0.98 (0.78-1.24) |
| Monomorphic | 825 | 0.86 (0.64-1.15) | 0.83 (0.67-1.02) |
| Other/unknown | 221 | 0.49 (0.24-1.00) | 0.56 (0.35-0.90) |
| By PTLD cell type | |||
| B cell | 1100 | 0.90 (0.70-1.16) | 0.85 (0.71-1.02) |
| T cell | 127 | 0.80 (0.36-1.74) | 1.09 (0.67-1.75) |
| Unknown | 403 | 0.70 (0.44-1.12) | 0.76 (0.56-1.03) |
| By PTLD EBV status | |||
| Negative | 238 | 1.04 (0.63-1.70) | 1.07 (0.75-1.53) |
| Positive | 785 | 0.75 (0.53-1.08) | 0.85 (0.69-1.05) |
| Unknown | 607 | 0.87 (0.63-1.20) | 0.75 (0.58-0.97) |
| By PTLD latency | |||
| Less than 1 y after transplantation | 627 | 0.71 (0.50-1.01) | 0.88 (0.69-1.11) |
| 1 to 4 y after transplantation | 535 | 1.02 (0.75-1.39) | 0.85 (0.67-1.07) |
| Over 5 y after transplantation | 468 | 0.77 (0.45-1.32) | 0.78 (0.58-1.06) |
| By organ type | |||
| Heart and/or lung | 513 | 1.53 (0.79-2.96) | 0.84 (0.63-1.11) |
| Kidney and/or pancreas | 698 | 0.55 (0.30-1.01) | 0.85 (0.67-1.08) |
| Liver | 382 | 0.83 (0.61-1.13) | 0.73 (0.56-0.96) |
| Other | 37 | 1.84 (0.52-6.53) | 0.65 (0.30-1.37) |
| . | Patients with PTLD, no. . | HCV+, HR (95% CI)* . | HCV status unknown, HR (95% CI)* . |
|---|---|---|---|
| Total | 1630 | 0.84 (0.68-1.05) | 0.84 (0.73-0.98) |
| By PTLD site | |||
| Liver | 208 | 1.06 (0.62-1.82) | 0.93 (0.62-1.40) |
| Nonliver | 1422 | 0.81 (0.64-1.03) | 0.83 (0.71-0.97) |
| Allograft | 266 | 1.11 (0.68-1.79) | 1.09 (0.78-1.54) |
| Nonallograft | 1364 | 0.80 (0.63-1.01) | 0.80 (0.68-0.94) |
| By PTLD pathology† | |||
| Polymorphic | 584 | 0.99 (0.69-1.41) | 0.98 (0.78-1.24) |
| Monomorphic | 825 | 0.86 (0.64-1.15) | 0.83 (0.67-1.02) |
| Other/unknown | 221 | 0.49 (0.24-1.00) | 0.56 (0.35-0.90) |
| By PTLD cell type | |||
| B cell | 1100 | 0.90 (0.70-1.16) | 0.85 (0.71-1.02) |
| T cell | 127 | 0.80 (0.36-1.74) | 1.09 (0.67-1.75) |
| Unknown | 403 | 0.70 (0.44-1.12) | 0.76 (0.56-1.03) |
| By PTLD EBV status | |||
| Negative | 238 | 1.04 (0.63-1.70) | 1.07 (0.75-1.53) |
| Positive | 785 | 0.75 (0.53-1.08) | 0.85 (0.69-1.05) |
| Unknown | 607 | 0.87 (0.63-1.20) | 0.75 (0.58-0.97) |
| By PTLD latency | |||
| Less than 1 y after transplantation | 627 | 0.71 (0.50-1.01) | 0.88 (0.69-1.11) |
| 1 to 4 y after transplantation | 535 | 1.02 (0.75-1.39) | 0.85 (0.67-1.07) |
| Over 5 y after transplantation | 468 | 0.77 (0.45-1.32) | 0.78 (0.58-1.06) |
| By organ type | |||
| Heart and/or lung | 513 | 1.53 (0.79-2.96) | 0.84 (0.63-1.11) |
| Kidney and/or pancreas | 698 | 0.55 (0.30-1.01) | 0.85 (0.67-1.08) |
| Liver | 382 | 0.83 (0.61-1.13) | 0.73 (0.56-0.96) |
| Other | 37 | 1.84 (0.52-6.53) | 0.65 (0.30-1.37) |
Adjusted for age, sex, race/ethnicity, and education. HCV− recipients were used as the referent group in all analyses.
PTLD pathology refers to morphologic classification of tumor cell size and shape as heterogeneous (″polymorphic PTLD″) or homogeneous (″monomorphic PTLD″). Both disease entities are thought to be monoclonal.